Topic
Topic
Sanofi has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance covering Dupixent across four dermatology and respiratory indications, moving the biologic toward coordinated provin…
Sanofi and pCPA have signed a Letter of Intent covering Dupixent across four dermatology and respiratory indications. The bundled…
Sanofi and Canada's pCPA signed a Letter of Intent this week covering Dupixent (dupilumab) across four dermatology and respirator…
Sanofi and the pCPA have signed a letter of intent on Dupixent pricing across four dermatology and respiratory indications, openi…
A plaintiff alleges dupilumab caused cutaneous T-cell lymphoma, a rare non-Hodgkin lymphoma that mimics eczema. The complaint tri…
Sanofi will pay $1 billion to expand its Regeneron alliance and fund a next-generation successor to Dupixent, doubling down on th…
Attorneys are competing for leadership posts in the Dupixent MDL, where plaintiffs allege Sanofi and Regeneron failed to warn abo…
Sanofi and Regeneron renew their Dupixent alliance ahead of the patent cliff, AstraZeneca commits $2B to Summit, and Lilly report…
Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to co-develop four long-acting antibodies targ…
